The research will be carried out in parallel with the phase III trial that evaluates the safety of the vaccine as a booster dose of any of the already authorized antigens.
The Spanish Agency for Medicines and Health Products (AEMPS) has authorized a new essay of the vaccine against covid pharmaceutical Hipra. The objective, on this occasion, is to determine and compare the immune response against the omicron variant in people who have received two doses of the AstraZeneca preparation, using Hipra as a booster dose; versus those who have received two doses of AstraZeneca, but with the Pfizer booster.
On November 15, another trial with volunteers who had received two doses of Pfizer was authorized and now it is being tested with the two doses of AstraZeneca. The test will be carried out in five spanish hospitals and will have about 300 volunteers who have not passed the covid.
In parallel to these studies, the phase III trial of the Hipra vaccine continues to assess the safety and tolerability as a booster dose of any of the currently authorized vaccines (Janssen, AstraZeneca, Moderna and Pfizer) in a larger sample of volunteers.
Related news
Hipra’s vaccine against COVID-19 is based on two structurally similar recombinant proteins, one corresponding to the alpha variant and the other to the beta variant, which come together to form a single structure called a dimer, and which is accompanied by an adjuvant that increases the immune response.
This combination is capable of generating a response against one of the proteins of the SARS-CoV-2 virus, known as protein S (from spike, called spike protein in Spanish). This platform, although it expresses proteins of two different variants, is the same one that has been used for the Novavax vaccine, which is in the process of being evaluated by the European Medicines Agency.